Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

Compared with placebo or pioglitazone, muraglitazar was associated with an excess incidence of the composite end point of death, major adverse cardiovascular events (MI, stroke, TIA), and CHF, which should not be approved to treat diabetes based on laboratory end points until safety is documented in a dedicated cardiovascular events trial.